Dysplasia epiphysealis hemimelica

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:1822OMIM:127800Q74.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Dysplasia epiphysealis hemimelica (DEH), also known as Trevor disease or tarso-epiphyseal aclasis, is a rare developmental skeletal disorder characterized by asymmetric overgrowth of cartilage affecting one or more epiphyses (the ends of long bones) on one side of the body. The condition predominantly affects the lower extremities, most commonly involving the ankle (talus), knee (distal femur or proximal tibia), and hip joints. The overgrowth typically occurs on the medial (inner) side of the affected limb, though lateral involvement has also been reported. The condition is roughly three times more common in males than females. Clinically, patients present with painless swelling or a hard mass near an affected joint, often noticed in early childhood. As the abnormal cartilaginous overgrowth progresses, it can lead to joint pain, restricted range of motion, limb length discrepancy, angular deformity (such as valgus or varus), and gait abnormalities. The disease may be classified as localized (affecting a single epiphysis), classic (involving multiple epiphyses in a single limb), or generalized (affecting an entire lower extremity). Radiographic imaging reveals irregular, lobulated ossification arising from the epiphysis, and MRI can help delineate the cartilaginous component. There is no known medical treatment for DEH. Management is primarily surgical and is indicated when the overgrowth causes pain, functional limitation, or significant deformity. Surgical excision of the osteocartilaginous mass is the standard approach, with the goal of preserving joint function and correcting alignment. Recurrence after surgery is possible, particularly in younger children with significant remaining growth. Long-term outcomes are generally favorable when the condition is identified early and managed appropriately, though secondary osteoarthritis may develop in affected joints over time.

Also known as:

Clinical phenotype terms— hover any for plain English:

Abnormal femoral neck morphologyHP:0003367Flattened femoral headHP:0008812Irregular epiphysesHP:0010582Asymmetric growthHP:0100555ExostosesHP:0100777
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Dysplasia epiphysealis hemimelica.

View clinical trials →

No actively recruiting trials found for Dysplasia epiphysealis hemimelica at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Dysplasia epiphysealis hemimelica community →

No specialists are currently listed for Dysplasia epiphysealis hemimelica.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Dysplasia epiphysealis hemimelica.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Dysplasia epiphysealis hemimelicaForum →

No community posts yet. Be the first to share your experience with Dysplasia epiphysealis hemimelica.

Start the conversation →

Latest news about Dysplasia epiphysealis hemimelica

No recent news articles for Dysplasia epiphysealis hemimelica.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Dysplasia epiphysealis hemimelica

What is Dysplasia epiphysealis hemimelica?

Dysplasia epiphysealis hemimelica (DEH), also known as Trevor disease or tarso-epiphyseal aclasis, is a rare developmental skeletal disorder characterized by asymmetric overgrowth of cartilage affecting one or more epiphyses (the ends of long bones) on one side of the body. The condition predominantly affects the lower extremities, most commonly involving the ankle (talus), knee (distal femur or proximal tibia), and hip joints. The overgrowth typically occurs on the medial (inner) side of the affected limb, though lateral involvement has also been reported. The condition is roughly three times

How is Dysplasia epiphysealis hemimelica inherited?

Dysplasia epiphysealis hemimelica follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Dysplasia epiphysealis hemimelica typically begin?

Typical onset of Dysplasia epiphysealis hemimelica is childhood. Age of onset can vary across affected individuals.